TLX -15.4%: the oncology company announced that they have pulled an application to market into Europe. The Danish Medicines Agency requested further testing numbers for their manufacturing practices to confirm the safety of Telix’s Illuccix product. The radioactive product is used in prostate cancer imaging and was on track for its first EU sales by mid-2023. The company expects to resubmit the application with the additional requests however they would not put a timeframe on the filing.
MM is bearish TLX around $4.50
Add To Hit List
